BK1326 Traditional Chinese Medicine
- 1049.181
- -21.197-1.98%
Kangchen Pharmaceutical (1681.HK): Leading nephrology proprietary Chinese medicine leader with high dividends and accelerated performance can be expected
Gushengtang (2273.HK): Maintaining rapid business growth in 1Q24
Big Bank Rating | Damo: Raising the target price of Chinese medicines to HK$5.4, attracting valuation
Gushengtang (02273.HK): The countercyclical advantage of leading traditional Chinese medicine chain diagnosis and treatment highlights the acceleration of expansion
Gushengtang (2273.HK): Performance is in line with expectations, continuous verification of Gusheng Medical's customer acquisition capability
China Resources Pharmaceuticals (03320.HK): Steady growth in performance, high-quality epitaxial expansion to expand new growth points
Kangchen Pharmaceutical (1681.HK): Significant advantages in the field of nephrology, performance continues to grow rapidly
China Resources Pharmaceutical (03320.HK): Performance meets expectations and further deepens marketing system transformation
Huaan Securities: Maintaining Luye Pharmaceutical's (02186) “Buy” Rating Rapid Growth in Sales Revenue in 2023
Gushengtang (2273.HK) 2023 Annual Results Review: High Growth, Significant TCM Center Leading Growth Accelerates
Luye Pharmaceutical (2186.HK): Sales revenue is growing rapidly, and business globalization is progressing steadily
Gushengtang (2273.HK): Annual results meet expectations and return to a rapid growth trajectory
Gushengtang (02273.HK): Outstanding performance, store expansion and doctor reserve guarantee growth
GUSHENGTANG(02273.HK):SOLID GROWTH OF OFFLINE BUSINESSES WITH CONTINUOUS BUSINESS EXPANSIONS
Gushengtang (2273.HK): Annual results post early forecast; strong upper limit demand promotes continued high growth
Gushengtang (2273.HK): Writing a strong growth movement, optimistic about making great strides in 24 years
Gushengtang (02273.HK): Annual performance grew rapidly and business layout continued to expand
Tong Ren Tang Technology (01666.HK): Revenue is in line with expectations, increased layout of core products
Shenwei Pharmaceutical (2877.HK): Rapid growth in performance, smooth progress in research and development of new drugs
Kangchen Pharmaceutical (1681.HK): Continued rapid growth in the field of nephrology